ADVERTISEMENT

Weighing the Impact of Obesity

Obese women with breast cancer are at higher risk for recurrence and death, but new findings suggest it may depend on cancer subtype. 

BY MELISSA WEBER
PUBLISHED THURSDAY, DECEMBER 9, 2010
The research has been pretty clear: Obese women with breast cancer are at higher risk for recurrence and death. But now, new findings suggest the poor outcome for obese patients depends on whether they have the most common subtype—estrogen receptor–positive, HER2-negative breast cancer. 

Obese women treated with chemotherapy after surgery had worse overall survival and disease-free survival than non-obese patients—but only if they had estrogen receptor–positive, or hormone-sensitive, cancers. The findings, presented Thursday at the San Antonio Breast Cancer Symposium, are the first to show that obesity’s harmful effects may be confined to this group of patients. Women with other types of breast cancer, however, shouldn’t consider themselves safe just yet, experts caution.

Obese Americans make up a third of the adult population. A person is considered obese if their body mass index—a calculation of body fat that uses weight in relation to height—is 30 or higher. So a 5-foot-5-inch woman would be considered obese at 180 pounds.

Using information from a previous clinical trial, investigators examined the relationship between body mass index and survival in early-stage patients. When researchers teased out the data by breast cancer subtype, they uncovered a trend toward worse survival only among obese women with hormone-sensitive tumors.

Hoping to confirm this finding, the researchers analyzed data from two other studies—one that included patients with estrogen receptor–positive cancers, and a second that comprised estrogen receptor–positive cancers. HER2 status was unknown in these two studies, but, like the first trial, patients had received chemotherapy after surgical removal of the tumor.

Based on combined data from the three studies, obese patients who do not have hormone-sensitive breast cancer appear to be spared the harmful effects of obesity, said lead investigator Joseph Sparano, MD, professor of medicine and women’s health at Albert Einstein College of Medicine and associate chairman of the department of oncology at Montefiore Medical Center in Bronx, New York. The findings, however, would need to be confirmed in other studies that look at all breast cancer subtypes, Sparano noted. 

Certainly the (women with ER-positive cancers) are at risk, but I wouldn’t begin to reassure the hormone receptor–negative obese women that they are not at risk. At the end of the day, the risk of obesity on prognosis won’t just be present in hormone receptor–positive patients.

Women with estrogen receptor–positive breast cancer should not feel protected, said Pamela Goodwin, MD, a clinician-scientist at Mount Sinai Hospital in Toronto and an associate professor of medicine at the University of Toronto. “Certainly the (women with ER-positive cancers) are at risk, but I wouldn’t begin to reassure the hormone receptor–negative obese women that they are not at risk,” said Goodwin, who was not involved in the study. “At the end of the day, the risk of obesity on prognosis won’t just be present in hormone receptor–positive patients.”

The most likely explanation for the findings may be that high insulin levels—a byproduct of obesity—are driving the growth of breast tumors, said Goodwin.

ADVERTISEMENT
Related Articles
Hope vs. Acceptance: The Metastatic Cancer See-Saw
Those of us living with metastatic cancer ride a see-saw between hope and acceptance.
Ovarian Suppression Emerges as Option for Younger, Premenopausal Breast Cancer Patients
BY JASON M. BRODERICK
Women with hormone receptor-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant Aromasin, according to results from the phase 3 SOFT trial.
Several Cancer Therapies Up for FDA Review in 2015
BY ANITA T. SHAFFER
The Food and Drug Administration’s calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.
Study Shows Women with Stage 1 HER2-Positive Breast Cancers Could Benefit from Herceptin
BY CHRISTINA IZZO
Results of a phase 2 study showed that women with small, stage 1 HER2-positive breast cancer who received a combination of lower-intensity chemotherapy and Herceptin following surgery were highly unlikely to have a recurrence.
Overcoming the Mental Battle of  Metastatic Cancer
The mental challenges of having stage 4 breast cancer are just as overwhelming as the physical ones.
Related Videos
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.
Breast Oncologist Beth Overmoyer Explains Results of Ovarian Suppression
Beth Overmoyer, a breast oncologist at Dana-Farber Cancer Institute, speaks on the results of the SOFT trial and its potential impact on young women with hormone receptor-positive breast cancer.
SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast Cancer
Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer.
Follow Up Study Data Draws Attention to Benefit, Side Effects of Adjuvant Chemotherapy in Breast Cancer
Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$